UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Uncover effective wealth building strategies in tough economic times to ensure your financial success. Start planning today!
19,592 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Goldman Sachs-backed GPIQ is carving out a niche as a high-yield Nasdaq-100 income vehicle. The fund uses a laddered ...
As Palantir tightens its client base, investors are weighing shares of its partners as cheaper ways to ride Palantir'...
Toobit unveils an AI-driven Agent Trade Kit that lets language models directly interact with its crypto exchange, tur...
Forecasts point to a higher 2027 social security cola as energy prices climb, potentially boosting benefits but signa...
Two crypto stock heavyweights drop sharply as the Clarity Act targets passive stablecoin yields, threatening Circle’s...
A two-year income lookback in Medicare pricing can surprise retirees after asset sales. This report explains how the ...
Investors are watching Eli Lilly as GLP-1 drugs like Mounjaro and Zepbound power growth. This article breaks down the...
New risk signals emerge as the S&P 500 grows more concentrated. Top 10 names and chipmakers now drive most of the mar...
MSGM's Q1 2026 commentary offers a clearer view of the year ahead for investors. This article decodes the msgm 2026 e...
A Texas teacher’s backpay story shows how the Fairness Act rewrites Social Security for public workers. Millions nati...
The 2026 tax rules lift the dependent care credit, easing family budgets as care costs rise. This report explains the...